The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots

Lazarian, G; Leroy, B; Theves, F; Hormi, M; Letestu, R; Eclache, V; Tueur, G; Ameur, A; Bidet, A; Cornillet-Lefebvre, P; Davi, F; Delabesse, E; Estienne, MH; Etancelin, P; Kosmider, O; Laibe, S; Muller, M; Nadal, N; Naguib, D; Pastoret, C; Poulain, S; Sujobert, P; Veronese, L; Imache, S; Lefebvre, V; Cymbalista, F; Baran-Marszak, F; Soussi, T

Baran-Marszak, F (通讯作者),Hop Avicenne, Hop Univ Paris Seine St Denis, AP HP, Serv Hematol Biol, Bobigny, France.;Soussi, T (通讯作者),Sorbonne Univ, Pl Jussieu, F-75005 Paris, France.;Soussi, T (通讯作者),Sorbonne Univ, Ctr Rech St Antoine, Hematopoiet & Leukem Dev, UMRS 938, F-75012 Paris, France.;Soussi, T (通讯作者),Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, S-75185 Uppsala, Sweden.

HUMAN MUTATION, 2023; 2023 ():

Abstract

TP53 aberrations are a major predictive factor of resistance to chemoimmunotherapy in chronic lymphocytic leukemia (CLL), and an assessment of them be......

Full Text Link